Navigation Links
Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market

GREENWOOD VILLAGE, Colo., May 19, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq Capital Market: AMPE) ("Ampio" or the "Company"), a company focused on new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that its common stock will commence trading on the NASDAQ Capital Market under the ticker symbol "AMPE" commencing today, May 19, 2011.

Don Wingerter, the Company's CEO, said, "We are extremely excited to begin trading on the NASDAQ Capital Market – a milestone in our market exposure. With this listing, we will no longer trade on the OTC Bulletin Board. We believe this listing is an excellent opportunity to introduce new investors to Ampio and our vision for product candidates we are currently developing."

About Ampio

The Company is currently performing a phase II clinical trial for the treatment of diabetic macular edema and is evaluating the data from a recently completed phase III clinical trial for the treatment of premature ejaculation.  Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction.  By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website,

Forward-Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties, such as changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Investor Relations
Ampio Pharmaceuticals, Inc.

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
2. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
3. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
4. Ampio Pharmaceuticals, Inc. Announces Appointment of New Chief Financial Officer to be Effective April 4, 2011
5. Kaiser Permanente Recognized as a J.D. Power 2011 Customer Service Champion
6. CHAMPION Study Published in The Lancet
7. Champions CFO Resigns
8. Champions Biotechnology Awarded $1.46 million in Grants
9. Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His Notoriety in New ExtenZe Spots from Inter/Media Advertising
10. Dr. Brian Boxer Wachler to be Honored With Olympic Gold Medal Bobsled Champion Steve Holcomb Alongside Apple CEO Steve Jobs, James Cameron, Dan Rather, Quincy Jones and Others at 2010 Vision Awards in Beverly Hills
11. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
Post Your Comments:
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... has always been a country of choice for global multi-center ... Europe in 2015 were tested in phase II-III clinical ... has always been a country of choice for global multi-center phase III ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... of adjunctive imaging is the focus of numerous abstracts accepted for presentation here, ... 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative breast ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, ... organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) ... exceptional special needs providers that excel in synthesizing the areas of clinical quality, ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... ... 01, 2015 , ... With FCPX Overlay: Grit , users can apply ... the possibilities are truly endless, all with a click of a mouse. Each user ... horizontal flip, depth of field and more, all within Final Cut Pro X. , ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Contact Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes ... and support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact ...
Breaking Medicine News(10 mins):